How should I manage a 79-year-old woman with neurofibromatosis type 1, hyperlipidemia, low bone density, chronic low body weight, insomnia, progressive isolated systolic hypertension, chronic hypotonic hyponatremia, and intermittent mild hyperkalemia?

Management of Severe Isolated Systolic Hypertension with Electrolyte Abnormalities in an Elderly Patient with NF1

Discontinue valsartan immediately and transition to a thiazide diuretic plus long-acting dihydropyridine calcium channel blocker combination for this 79-year-old woman with severe isolated systolic hypertension (systolic BP 150-200 mmHg), chronic hyponatremia (sodium 122-133 mmol/L), and recurrent hyperkalemia (potassium 5.2-5.4 mmol/L). The temporal relationship between valsartan initiation and both electrolyte disturbances, combined with worsening hyperkalemia after dose escalation, strongly implicates the ARB as a primary contributor to her metabolic derangements 1, 2, 3.

Blood Pressure Management Strategy

First-Line Therapy for Isolated Systolic Hypertension

For isolated systolic hypertension in elderly patients, initial therapy should combine a thiazide or thiazide-like diuretic with a long-acting dihydropyridine calcium channel blocker 1, 2, 3. This combination is Grade A evidence specifically for isolated systolic hypertension and addresses multiple pathophysiologic mechanisms:

• Thiazide/thiazide-like diuretics (chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg daily) reduce systolic BP through volume reduction and arterial compliance improvement 1, 2, 4
• Long-acting dihydropyridine calcium channel blockers (amlodipine 5-10 mg daily) directly address arterial stiffness and reduce pulse pressure 1, 2, 3

This combination is particularly appropriate given her severe aortic atherosclerosis, markedly elevated intrarenal resistive indices (0.92-0.96), and widened pulse pressure (132 mmHg), all suggesting arterial stiffness as the dominant mechanism 2, 4.

Blood Pressure Target

Target systolic BP of 120-140 mmHg if tolerated, with gradual titration given her age and frailty risk 1, 2, 4. The 2014 Canadian guidelines support treatment initiation at SBP ≥160 mmHg in elderly patients (Grade A evidence from HYVET trial), with demonstrated reduction in cardiovascular events and all-cause mortality 1. However, exercise caution with aggressive lowering in frail elderly patients 1, 3. Her current readings of 150-200 mmHg clearly warrant treatment, but dose escalation should be gradual with close monitoring for orthostatic hypotension 2.

Why ARBs Must Be Discontinued

Valsartan is directly implicated in both her hyponatremia and hyperkalemia:

1. Temporal relationship: Sodium was normal (141 mmol/L) immediately before valsartan initiation, then dropped to 133 mmol/L one month later, eventually reaching 122 mmol/L 5
2. Dose-response: Potassium increased from baseline 5.2 to 5.4 mmol/L after valsartan dose escalation from 80 to 160 mg 5
3. Mechanism: ARBs cause hyperkalemia through aldosterone suppression and can rarely cause SIADH-like hyponatremia 5

The 2025 AHA/ACC guidelines explicitly state that hyperkalemia may be caused by ARBs, especially in combination with other RAAS inhibitors or in CKD settings, and ACEi and ARB should not be used concurrently 5.

Electrolyte Management

Hyponatremia Approach

The hyponatremia (chronic baseline 129-133 mmol/L, acute nadir 122 mmol/L) requires:

1. Discontinue valsartan as the likely precipitant 5
2. Assess dietary solute intake: Her chronic low body weight (BMI 17) and limited caloric intake may contribute to low-solute hyponatremia. Encourage adequate protein intake (minimum 0.8-1.0 g/kg/day) to increase urinary solute excretion
3. Fluid restriction to 1000-1500 mL/day while monitoring response
4. Monitor sodium closely: Check basic metabolic panel 1 week after valsartan discontinuation, then 2-4 weeks after initiating thiazide diuretic 5

Critical caveat: Thiazide diuretics can cause hyponatremia, particularly in elderly women 5, 4. However, the benefit for BP control outweighs this risk if:

• Start with low-dose chlorthalidone (12.5 mg) or indapamide (1.25 mg)
• Check sodium 2-4 weeks after initiation 5
• If sodium drops below 130 mmol/L, reduce diuretic dose or switch to loop diuretic for BP control (though less effective for isolated systolic hypertension) 6

Hyperkalemia Management

The recurrent mild hyperkalemia (5.2-5.4 mmol/L) should resolve with valsartan discontinuation:

1. Discontinue valsartan - this addresses the primary driver of recent hyperkalemia 5
2. Thiazide diuretics cause hypokalemia, which will counterbalance her baseline tendency toward mild hyperkalemia 5
3. Monitor potassium 2-4 weeks after medication changes 5
4. Avoid potassium supplementation unless potassium drops below 3.5 mmol/L on thiazide therapy 1, 7, 3

The combination of thiazide diuretic (which lowers potassium) with calcium channel blocker (potassium-neutral) provides complementary electrolyte effects 5.

NF1-Specific Considerations

Secondary Hypertension Evaluation

Her NF1 raises concern for pheochromocytoma, but current workup is reassuring:

• Urine metanephrines showed only mild elevation of metanephrine (167, normal <153) with normal normetanephrine (329) and total metanephrines (496) 8
• No adrenal mass on CT abdomen/pelvis
• No paroxysmal symptoms (headache, palpitations, diaphoresis)

However, NF1-associated pheochromocytomas can present late (even at age 79) and may be bilateral 8. The mild metanephrine elevation warrants:

• Repeat 24-hour urine fractionated metanephrines in 6-12 months
• Maintain high clinical suspicion if BP becomes refractory to medical therapy
• Consider repeat abdominal imaging if metanephrines increase or symptoms develop

Renal Vascular Disease

The markedly elevated intrarenal resistive indices (0.92-0.96) with <60% renal artery stenosis suggest:

• Intrarenal microvascular disease rather than main renal artery stenosis 9
• Systemic arterial stiffness contributing to elevated resistive indices
• NF1-associated renal artery microaneurysms are rare but reported 9

This does not change management - thiazide plus calcium channel blocker remains appropriate. ACE inhibitors or ARBs would typically be considered for renovascular disease, but are contraindicated here due to electrolyte complications 5.

Vitamin D and Bone Health

Her history of vitamin D excess while taking supplements and current low bone density require:

• Check 25-OH vitamin D level (NF1 patients have high prevalence of vitamin D deficiency and bone mineral abnormalities) 10, 11
• If deficient, supplement with cholecalciferol 800-1000 IU daily with calcium 1200 mg daily 10
• Avoid excessive supplementation given her prior vitamin D excess
• Monitor calcium and vitamin D levels every 6-12 months

Practical Implementation Algorithm

Week 0 (Immediate):

1. Discontinue valsartan 160 mg
2. Start chlorthalidone 12.5 mg daily (or indapamide 1.25 mg if chlorthalidone unavailable)
3. Continue amlodipine 5 mg daily
4. Implement fluid restriction to 1000-1500 mL/day
5. Encourage adequate dietary protein and sodium intake (avoid severe sodium restriction given hyponatremia risk)

Week 1:

• Check basic metabolic panel (sodium, potassium, creatinine, bicarbonate)
• Assess for orthostatic hypotension (BP supine and after 1-3 minutes standing)
• Review home BP log

Week 2-4:

• Repeat basic metabolic panel
• If sodium remains <130 mmol/L: reduce chlorthalidone to every other day or switch to loop diuretic
• If potassium <3.5 mmol/L: add potassium supplementation or switch to potassium-sparing combination
• If systolic BP remains >150 mmHg: increase amlodipine to 10 mg daily

Week 6-8:

• If systolic BP remains >140 mmHg on amlodipine 10 mg + chlorthalidone 12.5 mg:
  • Increase chlorthalidone to 25 mg daily (if electrolytes stable)
  • OR add third agent (consider alpha-blocker, centrally acting agent, or beta-blocker if no contraindications) 1, 3

Ongoing Monitoring:

• Home BP monitoring twice daily
• Basic metabolic panel every 3 months once stable
• Repeat urine metanephrines in 6-12 months
• Annual assessment for orthostatic hypotension
• Monitor for symptoms of hyponatremia (confusion, falls, weakness)

Critical Pitfalls to Avoid

Do not continue ARB therapy despite its theoretical benefits for arterial stiffness - the electrolyte complications outweigh any BP benefit in this patient 5.

Do not combine ACE inhibitor with ARB - this increases risk of hyperkalemia, hypotension, and renal dysfunction without additional benefit 7, 5.

Do not aggressively lower BP in first 2-4 weeks - gradual titration reduces risk of orthostatic hypotension, falls, and cerebral hypoperfusion in elderly patients 1, 2.

Do not ignore the low BMI and dietary intake - inadequate solute intake impairs free water excretion and may contribute to hyponatremia independent of medications.

Do not assume normal creatinine equals normal renal function - her creatinine 0.68-0.86 mg/dL likely overestimates GFR given her low muscle mass (BMI 17). Calculate eGFR and monitor for changes with medication adjustments 5.

Monitor sodium closely when starting thiazide - elderly women are at highest risk for thiazide-induced hyponatremia, which can develop acutely even weeks after drug initiation 5, 4.